- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02337569
A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency
April 15, 2019 updated by: Nobelpharma
The objective of this study is to evaluate efficacy and safety of NPC-02 in patients with Zinc Deficiency.
Study Overview
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan
- Osaka Medical Center for Cancer and Cardiovascular Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The serum zinc concentrations are under the normal level before registration
Exclusion Criteria:
- Heavy hepatitis
- Malignant tumor
- Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.
- The serum albumin under 2.8 g/dL
- Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)
- Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration
- Pregnant, suspected pregnant, lactating, patients who wish to have a child
- Patient who participated in other clinical trials within 12 weeks before registration
- Unsuitable as a target of this clinical trial judged by doctor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NPC-02
Oral dose
|
|
Placebo Comparator: Placebo
Oral dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change amount of serum zinc concentration between starting and 8 weeks after dosing
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
January 9, 2015
First Submitted That Met QC Criteria
January 12, 2015
First Posted (Estimate)
January 13, 2015
Study Record Updates
Last Update Posted (Actual)
April 17, 2019
Last Update Submitted That Met QC Criteria
April 15, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- NPC-02-4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Zinc Deficiency
-
NobelpharmaCompleted
-
Swiss Federal Institute of TechnologyHarvestPlusCompleted
-
Prof. Michael B. ZimmermannUniversité d'Abomey-CalaviCompleted
-
University of California, DavisHelen Keller International; Cheikh Anta Diop University, Senegal; Global Alliance...Completed
-
International Centre for Diarrhoeal Disease Research...University of California, DavisCompleted
-
University of California, DavisHelen Keller International; Université Polytechnique de Bobo-Dioulasso; NutrisetCompletedZinc DeficiencyBurkina Faso
-
Swiss Federal Institute of TechnologyHarvestPlusCompletedZinc Deficiency
-
Wageningen UniversityETH Zurich; Maseno UniversityCompletedZinc DeficiencyKenya
-
University of California, DavisUSDA, Western Human Nutrition Research CenterCompleted
-
University of California, DavisHelen Keller International; Cheikh Anta Diop University, Senegal; Global Alliance...Completed
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France